ID   ADA_HUMAN               Reviewed;         363 AA.
AC   P00813; Q53F92; Q6LA59;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 206.
DE   RecName: Full=Adenosine deaminase;
DE            EC=3.5.4.4 {ECO:0000269|PubMed:16670267, ECO:0000269|PubMed:23193172, ECO:0000269|PubMed:8452534};
DE   AltName: Full=Adenosine aminohydrolase;
GN   Name=ADA; Synonyms=ADA1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6090454;
RA   Daddona P.E., Shewach D.S., Kelley W.N., Argos P., Markham A.F.,
RA   Orkin S.H.;
RT   "Human adenosine deaminase. cDNA and complete primary amino acid
RT   sequence.";
RL   J. Biol. Chem. 259:12101-12106(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6546794; DOI=10.1093/nar/12.5.2439;
RA   Wiginton D.A., Adrian G.S., Hutton J.J.;
RT   "Sequence of human adenosine deaminase cDNA including the coding
RT   region and a small intron.";
RL   Nucleic Acids Res. 12:2439-2446(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3839456;
RA   Valerio D., Duyvesteyn M.G.C., Dekker B.M.M., Weeda G., Berkvens T.M.,
RA   van der Voorn L., van Ormondt H., van der Eb A.J.;
RT   "Adenosine deaminase: characterization and expression of a gene with a
RT   remarkable promoter.";
RL   EMBO J. 4:437-443(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3028473; DOI=10.1021/bi00373a017;
RA   Wiginton D.A., Kaplan D.J., States J.C., Akeson A.L., Perme C.M.,
RA   Bilyk I.J., Vaughn A.J., Lattier D.L., Hutton J.J.;
RT   "Complete sequence and structure of the gene for human adenosine
RT   deaminase.";
RL   Biochemistry 25:8234-8244(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Thymus;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-11, ACETYLATION AT ALA-2, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V.;
RL   Submitted (AUG-2004) to UniProtKB.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 141-363.
RX   PubMed=6688808;
RA   Orkin S.H., Daddona P.E., Shewach D.S., Markham A.F., Bruns G.A.,
RA   Goff S.C., Kelley W.N.;
RT   "Molecular cloning of human adenosine deaminase gene sequences.";
RL   J. Biol. Chem. 258:12753-12756(1983).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND SUBCELLULAR LOCATION.
RX   PubMed=8452534; DOI=10.1042/bj2900457;
RA   Lindley E.R., Pisoni R.L.;
RT   "Demonstration of adenosine deaminase activity in human fibroblast
RT   lysosomes.";
RL   Biochem. J. 290:457-462(1993).
RN   [11]
RP   INTERACTION WITH DPP4, AND SUBCELLULAR LOCATION.
RX   PubMed=8101391; DOI=10.1126/science.8101391;
RA   Kameoka J., Tanaka T., Nojima Y., Schlossman S.F., Morimoto C.;
RT   "Direct association of adenosine deaminase with a T cell activation
RT   antigen, CD26.";
RL   Science 261:466-469(1993).
RN   [12]
RP   INTERACTION WITH DPP4.
RX   PubMed=7907293; DOI=10.1002/eji.1830240311;
RA   De Meester I., Vanham G., Kestens L., Vanhoof G., Bosmans E.,
RA   Gigase P., Scharpe S.;
RT   "Binding of adenosine deaminase to the lymphocyte surface via CD26.";
RL   Eur. J. Immunol. 24:566-570(1994).
RN   [13]
RP   INTERACTION WITH DPP4.
RX   PubMed=10951221; DOI=10.1046/j.1432-1327.2000.01634.x;
RA   Durinx C., Lambeir A.M., Bosmans E., Falmagne J.B., Berghmans R.,
RA   Haemers A., Scharpe S., De Meester I.;
RT   "Molecular characterization of dipeptidyl peptidase activity in serum:
RT   soluble CD26/dipeptidyl peptidase IV is responsible for the release of
RT   X-Pro dipeptides.";
RL   Eur. J. Biochem. 267:5608-5613(2000).
RN   [14]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11772392; DOI=10.1042/0264-6021:3610203;
RA   Gines S., Marino M., Mallol J., Canela E.I., Morimoto C.,
RA   Callebaut C., Hovanessian A., Casado V., Lluis C., Franco R.;
RT   "Regulation of epithelial and lymphocyte cell adhesion by adenosine
RT   deaminase-CD26 interaction.";
RL   Biochem. J. 361:203-209(2002).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH DPP4 AND PLG.
RX   PubMed=15016824; DOI=10.1074/jbc.M401023200;
RA   Gonzalez-Gronow M., Hershfield M.S., Arredondo-Vega F.X., Pizzo S.V.;
RT   "Cell surface adenosine deaminase binds and stimulates plasminogen
RT   activation on 1-LN human prostate cancer cells.";
RL   J. Biol. Chem. 279:20993-20998(2004).
RN   [16]
RP   INTERACTION WITH DPP4.
RX   PubMed=14691230; DOI=10.1110/ps.03352504;
RA   Aertgeerts K., Ye S., Shi L., Prasad S.G., Witmer D., Chi E.,
RA   Sang B.C., Wijnands R.A., Webb D.R., Swanson R.V.;
RT   "N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on
RT   enzyme activity, homodimer formation, and adenosine deaminase
RT   binding.";
RL   Protein Sci. 13:145-154(2004).
RN   [17]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INDUCTION BY HYPOXIA.
RX   PubMed=16670267; DOI=10.1182/blood-2006-02-001016;
RA   Eltzschig H.K., Faigle M., Knapp S., Karhausen J., Ibla J.,
RA   Rosenberger P., Odegard K.C., Laussen P.C., Thompson L.F.,
RA   Colgan S.P.;
RT   "Endothelial catabolism of extracellular adenosine during hypoxia: the
RT   role of surface adenosine deaminase and CD26.";
RL   Blood 108:1602-1610(2006).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-54 AND LYS-232, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=20959412; DOI=10.1189/jlb.1009696;
RA   Martinez-Navio J.M., Casanova V., Pacheco R., Naval-Macabuhay I.,
RA   Climent N., Garcia F., Gatell J.M., Mallol J., Gallart T., Lluis C.,
RA   Franco R.;
RT   "Adenosine deaminase potentiates the generation of effector, memory,
RT   and regulatory CD4+ T cells.";
RL   J. Leukoc. Biol. 89:127-136(2011).
RN   [22]
RP   FUNCTION.
RX   PubMed=21919946; DOI=10.1111/j.1439-0272.2011.01231.x;
RA   Rostampour F., Biglari M., Vaisi-Raygani A., Salimi S., Tavilani H.;
RT   "Adenosine deaminase activity in fertile and infertile men.";
RL   Andrologia 44:586-589(2012).
RN   [23]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   MUTAGENESIS OF LEU-58; ASP-60; PHE-61; LEU-62; LYS-64; PHE-65; ASP-66;
RP   MET-69; ILE-115; ASN-118; MET-155; HIS-157; GLY-184; ASP-185 AND
RP   LEU-194.
RX   PubMed=23193172; DOI=10.1096/fj.12-212621;
RA   Gracia E., Farre D., Cortes A., Ferrer-Costa C., Orozco M., Mallol J.,
RA   Lluis C., Canela E.I., McCormick P.J., Franco R., Fanelli F.,
RA   Casado V.;
RT   "The catalytic site structural gate of adenosine deaminase
RT   allosterically modulates ligand binding to adenosine receptors.";
RL   FASEB J. 27:1048-1061(2013).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.52 ANGSTROMS) OF 5-363 IN COMPLEX WITH NICKEL
RP   IONS AND 2-DEAOXYADENOSINE, AND COFACTOR.
RG   Structural genomics consortium (SGC);
RT   "The crystal structure of human adenosine deaminase.";
RL   Submitted (AUG-2009) to the PDB data bank.
RN   [25]
RP   VARIANTS ADASCID TRP-76; PRO-107; GLN-149; CYS-211; THR-215 AND
RP   LEU-274.
RX   PubMed=2166947; DOI=10.1073/pnas.87.16.6171;
RA   Hirschhorn R., Tzall S., Ellenbogen A.;
RT   "Hot spot mutations in adenosine deaminase deficiency.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:6171-6175(1990).
RN   [26]
RP   VARIANT ADA*2 ASN-8.
RX   PubMed=8031011; DOI=10.1111/j.1469-1809.1994.tb00720.x;
RA   Hirschhorn R., Yang D.R., Israni A.;
RT   "An Asp8Asn substitution results in the adenosine deaminase (ADA)
RT   genetic polymorphism (ADA 2 allozyme): occurrence on different
RT   chromosomal backgrounds and apparent intragenic crossover.";
RL   Ann. Hum. Genet. 58:1-9(1994).
RN   [27]
RP   VARIANTS ADASCID.
RX   PubMed=6208479; DOI=10.1128/MCB.4.9.1712;
RA   Adrian G.S., Wiginton D.A., Hutton J.;
RT   "Structure of adenosine deaminase mRNAs from normal and adenosine
RT   deaminase-deficient human cell lines.";
RL   Mol. Cell. Biol. 4:1712-1717(1984).
RN   [28]
RP   VARIANT ADASCID GLN-101.
RX   PubMed=3839802; DOI=10.1172/JCI112050;
RA   Bonthron D.T., Markham A.F., Ginsburg D., Orkin S.H.;
RT   "Identification of a point mutation in the adenosine deaminase gene
RT   responsible for immunodeficiency.";
RL   J. Clin. Invest. 76:894-897(1985).
RN   [29]
RP   VARIANTS ADASCID TRP-101; HIS-211 AND VAL-329.
RX   PubMed=3182793;
RA   Akeson A.L., Wiginton D.A., Dusing M.R., States J.C., Hutton J.J.;
RT   "Mutant human adenosine deaminase alleles and their expression by
RT   transfection into fibroblasts.";
RL   J. Biol. Chem. 263:16291-16296(1988).
RN   [30]
RP   VARIANT ADASCID GLN-297.
RX   PubMed=2783588; DOI=10.1172/JCI113909;
RA   Hirschhorn R., Tzall S., Ellenbogen A., Orkin S.H.;
RT   "Identification of a point mutation resulting in a heat-labile
RT   adenosine deaminase (ADA) in two unrelated children with partial ADA
RT   deficiency.";
RL   J. Clin. Invest. 83:497-501(1989).
RN   [31]
RP   VARIANTS ADASCID CYS-156 AND LEU-291.
RX   PubMed=1284479; DOI=10.1002/humu.1380010214;
RA   Hirschhorn R.;
RT   "Identification of two new missense mutations (R156C and S291L) in two
RT   ADA-SCID patients unusual for response to therapy with partial
RT   exchange transfusions.";
RL   Hum. Mutat. 1:166-168(1992).
RN   [32]
RP   VARIANTS ADASCID LEU-101; HIS-156; MET-177; ARG-216 AND LEU-291.
RX   PubMed=8227344; DOI=10.1172/JCI116833;
RA   Santisteban I., Arredondo-Vega F.X., Kelly S., Mary A., Fischer A.,
RA   Hummell D.S., Lawton A., Sorensen R.U., Stiehm E.R., Uribe L.,
RA   Weinberg K., Hershfield M.S.;
RT   "Novel splicing, missense, and deletion mutations in seven adenosine
RT   deaminase-deficient patients with late/delayed onset of combined
RT   immunodeficiency disease. Contribution of genotype to phenotype.";
RL   J. Clin. Invest. 92:2291-2302(1993).
RN   [33]
RP   VARIANT ADASCID ARG-20.
RX   PubMed=8299233; DOI=10.1006/clin.1994.1026;
RA   Yang D.R., Huie M.L., Hirschhorn R.;
RT   "Homozygosity for a missense mutation (G20R) associated with neonatal
RT   onset adenosine deaminase-deficient severe combined immunodeficiency
RT   (ADA-SCID).";
RL   Clin. Immunol. Immunopathol. 70:171-175(1994).
RN   [34]
RP   VARIANTS ARG-80 AND GLN-142.
RX   PubMed=8589684; DOI=10.1093/hmg/4.11.2081;
RA   Santisteban I., Arredondo-Vega F.X., Kelly S., Loubser M., Meydan N.,
RA   Roifman C., Howell P.L., Bowen T., Weinberg K.I., Schroeder M.L.,
RA   Hershfield M.S.;
RT   "Three new adenosine deaminase mutations that define a splicing
RT   enhancer and cause severe and partial phenotypes: implications for
RT   evolution of a CpG hotspot and expression of a transduced ADA cDNA.";
RL   Hum. Mol. Genet. 4:2081-2087(1995).
RN   [35]
RP   VARIANTS ADASCID ASP-15; ASP-83 AND ASP-179.
RX   PubMed=7599635; DOI=10.1002/humu.1380050309;
RA   Santisteban I., Arredondo-Vega F.X., Kelly S., Debre M., Fisher A.,
RA   Perignon J.L., Hilman B., Eldahr J., Dreyfus D.H., Gelfand E.W.,
RA   Howell P.L., Hershfield M.S.;
RT   "Four new adenosine deaminase mutations, altering a zinc-binding
RT   histidine, two conserved alanines, and a 5' splice site.";
RL   Hum. Mutat. 5:243-250(1995).
RN   [36]
RP   VARIANTS MET-152 AND ILE-233.
RX   PubMed=9225964; DOI=10.1007/s004390050460;
RA   Hirschhorn R., Borkowsky W., Jiang C.-K., Yang D.R., Jenkins T.;
RT   "Two newly identified mutations (Thr233Ile and Leu152Met) in partially
RT   adenosine deaminase-deficient (ADA-) individuals that result in
RT   differing biochemical and metabolic phenotypes.";
RL   Hum. Genet. 100:22-29(1997).
RN   [37]
RP   VARIANTS ADASCID CYS-97 AND VAL-106, CHARACTERIZATION OF VARIANTS
RP   ADASCID CYS-97; VAL-106; CYS-211 AND THR-215, AND CHARACTERIZATION OF
RP   VARIANT ILE-233.
RX   PubMed=9361033; DOI=10.1093/hmg/6.13.2271;
RA   Jiang C., Hong R., Horowitz S.D., Kong X., Hirschhorn R.;
RT   "An adenosine deaminase (ADA) allele contains two newly identified
RT   deleterious mutations (Y97C and L106V) that interact to abolish enzyme
RT   activity.";
RL   Hum. Mol. Genet. 6:2271-2278(1997).
RN   [38]
RP   VARIANTS ADASCID CYS-74; MET-129; GLU-140; TRP-149 AND PRO-199.
RX   PubMed=10200056;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:6<482::AID-HUMU14>3.3.CO;2-8;
RA   Arrendondo-Vega F.X., Santisteban I., Notarangelo L.D., El Dahr J.,
RA   Buckley R., Roifman C., Conley M.E., Hershfield M.S.;
RT   "Seven novel mutations in the adenosine deaminase (ADA) gene in
RT   patients with severe and delayed onset combined immunodeficiency:
RT   G74C, V129M, G140E, R149W, Q199P, 462delG, and E337del.";
RL   Hum. Mutat. 11:482-482(1998).
RN   [39]
RP   EFFECT OF VARIANT ADA*2 ASN-8 ON SLEEP.
RX   PubMed=16221767; DOI=10.1073/pnas.0505414102;
RA   Retey J.V., Adam M., Honegger E., Khatami R., Luhmann U.F.O.,
RA   Jung H.H., Berger W., Landolt H.-P.;
RT   "A functional genetic variation of adenosine deaminase affects the
RT   duration and intensity of deep sleep in humans.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:15676-15681(2005).
RN   [40]
RP   VARIANT [LARGE SCALE ANALYSIS] GLN-142.
RX   PubMed=18772397; DOI=10.1126/science.1164368;
RA   Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P.,
RA   Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B.,
RA   Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T.,
RA   Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D.,
RA   Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C.,
RA   Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N.,
RA   Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W.;
RT   "Core signaling pathways in human pancreatic cancers revealed by
RT   global genomic analyses.";
RL   Science 321:1801-1806(2008).
RN   [41]
RP   VARIANT ADA*2 ASN-8, AND CHARACTERIZATION OF VARIANT ASN-8.
RX   PubMed=21734253; DOI=10.1093/cercor/bhr173;
RA   Bachmann V., Klaus F., Bodenmann S., Schaefer N., Brugger P.,
RA   Huber S., Berger W., Landolt H.P.;
RT   "Functional ADA polymorphism increases sleep depth and reduces
RT   vigilant attention in humans.";
RL   Cereb. Cortex 22:962-970(2012).
RN   [42]
RP   VARIANT ADA*2 ASN-8, CHARACTERIZATION OF VARIANT ASN-8, AND FUNCTION.
RX   PubMed=26166670; DOI=10.1016/j.urology.2015.06.034;
RA   Fattahi A., Khodadadi I., Amiri I., Latifi Z., Ghorbani M.,
RA   Tavilani H.;
RT   "The Role of G22 A Adenosine Deaminase 1 Gene Polymorphism and the
RT   Activities of ADA Isoenzymes in Fertile and Infertile Men.";
RL   Urology 86:730-734(2015).
CC   -!- FUNCTION: Catalyzes the hydrolytic deamination of adenosine and 2-
CC       deoxyadenosine (PubMed:8452534, PubMed:16670267). Plays an
CC       important role in purine metabolism and in adenosine homeostasis.
CC       Modulates signaling by extracellular adenosine, and so contributes
CC       indirectly to cellular signaling events. Acts as a positive
CC       regulator of T-cell coactivation, by binding DPP4
CC       (PubMed:20959412). Its interaction with DPP4 regulates lymphocyte-
CC       epithelial cell adhesion (PubMed:11772392). Enhances dendritic
CC       cell immunogenicity by affecting dendritic cell costimulatory
CC       molecule expression and cytokines and chemokines secretion (By
CC       similarity). Enhances CD4+ T-cell differentiation and
CC       proliferation (PubMed:20959412). Acts as a positive modulator of
CC       adenosine receptors ADORA1 and ADORA2A, by enhancing their ligand
CC       affinity via conformational change (PubMed:23193172). Stimulates
CC       plasminogen activation (PubMed:15016824). Plays a role in male
CC       fertility (PubMed:21919946, PubMed:26166670). Plays a protective
CC       role in early postimplantation embryonic development (By
CC       similarity). {ECO:0000250|UniProtKB:P03958,
CC       ECO:0000250|UniProtKB:P56658, ECO:0000269|PubMed:11772392,
CC       ECO:0000269|PubMed:15016824, ECO:0000269|PubMed:16670267,
CC       ECO:0000269|PubMed:20959412, ECO:0000269|PubMed:21919946,
CC       ECO:0000269|PubMed:23193172, ECO:0000269|PubMed:26166670,
CC       ECO:0000269|PubMed:8452534}.
CC   -!- CATALYTIC ACTIVITY: Adenosine + H(2)O = inosine + NH(3).
CC       {ECO:0000269|PubMed:16670267, ECO:0000269|PubMed:23193172,
CC       ECO:0000269|PubMed:8452534}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000305|Ref.24};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000305|Ref.24};
CC   -!- ENZYME REGULATION: Inhibited by Cu(2+) and Hg(2+), coformycin,
CC       deoxycoformycin (dCF), 2-deoxyadenosine, 6-methylaminopurine
CC       riboside, 2-3-iso-propylidene-adenosine and erythro-9-(2-hydroxy-
CC       3-nonyl)adenine. {ECO:0000269|PubMed:16670267,
CC       ECO:0000269|PubMed:8452534}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=37 uM for adenosine (at 25 degrees Celsius and pH 5.5)
CC         {ECO:0000269|PubMed:8452534};
CC         Vmax=41 umol/min/mg enzyme {ECO:0000269|PubMed:23193172};
CC   -!- SUBUNIT: Interacts with DPP4 (via extracellular domain)
CC       (PubMed:10951221, PubMed:14691230, PubMed:7907293, PubMed:8101391,
CC       PubMed:15016824). Interacts with PLG (via Kringle 4 domain); the
CC       interaction stimulates PLG activation when in complex with DPP4
CC       (PubMed:15016824). {ECO:0000269|PubMed:10951221,
CC       ECO:0000269|PubMed:14691230, ECO:0000269|PubMed:15016824,
CC       ECO:0000269|PubMed:7907293, ECO:0000269|PubMed:8101391}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11772392,
CC       ECO:0000269|PubMed:8101391}; Peripheral membrane protein;
CC       Extracellular side. Cell junction {ECO:0000269|PubMed:11772392}.
CC       Cytoplasmic vesicle lumen {ECO:0000250|UniProtKB:P03958}.
CC       Cytoplasm {ECO:0000250}. Lysosome {ECO:0000269|PubMed:8452534}.
CC       Note=Colocalized with DPP4 at the cell surface.
CC       {ECO:0000269|PubMed:11772392}.
CC   -!- TISSUE SPECIFICITY: Found in all tissues, occurs in large amounts
CC       in T-lymphocytes (PubMed:20959412). Expressed at the time of
CC       weaning in gastrointestinal tissues.
CC       {ECO:0000269|PubMed:20959412}.
CC   -!- INDUCTION: Up-regulated by hypoxia. {ECO:0000269|PubMed:16670267}.
CC   -!- POLYMORPHISM: There is a common allele, ADA*2, also known as the
CC       ADA 2 allozyme. It is associated with the reduced metabolism of
CC       adenosine to inosine. It specifically enhances deep sleep and
CC       slow-wave activity (SWA) during sleep.
CC       {ECO:0000269|PubMed:16221767}.
CC   -!- DISEASE: Severe combined immunodeficiency autosomal recessive T-
CC       cell-negative/B-cell-negative/NK-cell-negative due to adenosine
CC       deaminase deficiency (ADASCID) [MIM:102700]: An autosomal
CC       recessive disorder accounting for about 50% of non-X-linked SCIDs.
CC       SCID refers to a genetically and clinically heterogeneous group of
CC       rare congenital disorders characterized by impairment of both
CC       humoral and cell-mediated immunity, leukopenia, and low or absent
CC       antibody levels. Patients with SCID present in infancy with
CC       recurrent, persistent infections by opportunistic organisms. The
CC       common characteristic of all types of SCID is absence of T-cell-
CC       mediated cellular immunity due to a defect in T-cell development.
CC       ADA deficiency has been diagnosed in chronically ill teenagers and
CC       adults (late or adult onset). Population and newborn screening
CC       programs have also identified several healthy individuals with
CC       normal immunity who have partial ADA deficiency.
CC       {ECO:0000269|PubMed:10200056, ECO:0000269|PubMed:1284479,
CC       ECO:0000269|PubMed:2166947, ECO:0000269|PubMed:2783588,
CC       ECO:0000269|PubMed:3182793, ECO:0000269|PubMed:3839802,
CC       ECO:0000269|PubMed:6208479, ECO:0000269|PubMed:7599635,
CC       ECO:0000269|PubMed:8227344, ECO:0000269|PubMed:8299233,
CC       ECO:0000269|PubMed:9361033}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the adenosine and AMP deaminases family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=ADAbase; Note=ADA mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/ADAbase/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Adenosine deaminase entry;
CC       URL="https://en.wikipedia.org/wiki/Adenosine_deaminase";
CC   -!- WEB RESOURCE: Name=Mendelian genes adenosine deaminase (ADA);
CC       Note=Leiden Open Variation Database (LOVD);
CC       URL="http://www.lovd.nl/ADA";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X02994; CAA26734.1; -; mRNA.
DR   EMBL; X02189; CAA26130.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; X02190; CAA26130.1; JOINED; Genomic_DNA.
DR   EMBL; X02191; CAA26130.1; JOINED; Genomic_DNA.
DR   EMBL; X02192; CAA26130.1; JOINED; Genomic_DNA.
DR   EMBL; X02193; CAA26130.1; JOINED; Genomic_DNA.
DR   EMBL; X02194; CAA26130.1; JOINED; Genomic_DNA.
DR   EMBL; X02195; CAA26130.1; JOINED; Genomic_DNA.
DR   EMBL; X02196; CAA26130.1; JOINED; Genomic_DNA.
DR   EMBL; X02197; CAA26130.1; JOINED; Genomic_DNA.
DR   EMBL; X02198; CAA26130.1; JOINED; Genomic_DNA.
DR   EMBL; X02199; CAA26130.1; JOINED; Genomic_DNA.
DR   EMBL; M13792; AAA78791.1; -; Genomic_DNA.
DR   EMBL; AL139352; CAH73885.1; -; Genomic_DNA.
DR   EMBL; Z97053; CAH73885.1; JOINED; Genomic_DNA.
DR   EMBL; Z97053; CAB09782.2; -; Genomic_DNA.
DR   EMBL; AL139352; CAB09782.2; JOINED; Genomic_DNA.
DR   EMBL; AK223397; BAD97117.1; -; mRNA.
DR   EMBL; BC007678; AAH07678.1; -; mRNA.
DR   EMBL; BC040226; AAH40226.1; -; mRNA.
DR   CCDS; CCDS13335.1; -.
DR   PIR; A91032; DUHUA.
DR   RefSeq; NP_000013.2; NM_000022.3.
DR   UniGene; Hs.654536; -.
DR   PDB; 1M7M; Model; -; A=1-363.
DR   PDB; 3IAR; X-ray; 1.52 A; A=5-363.
DR   PDBsum; 1M7M; -.
DR   PDBsum; 3IAR; -.
DR   ProteinModelPortal; P00813; -.
DR   SMR; P00813; -.
DR   BioGrid; 106614; 20.
DR   DIP; DIP-371N; -.
DR   IntAct; P00813; 4.
DR   MINT; MINT-5000852; -.
DR   STRING; 9606.ENSP00000361965; -.
DR   BindingDB; P00813; -.
DR   ChEMBL; CHEMBL1910; -.
DR   DrugBank; DB07783; 1-((1R)-1-(HYDROXYMETHYL)-3-{6-[(3-PHENYLPROPANOYL)AMINO]-1H-INDOL-1-YL}PROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE.
DR   DrugBank; DB04218; 1-Deaza-Adenosine.
DR   DrugBank; DB00640; Adenosine.
DR   DrugBank; DB00975; Dipyridamole.
DR   DrugBank; DB00974; Edetic Acid.
DR   DrugBank; DB05057; Erdosteine.
DR   DrugBank; DB02616; FR117016.
DR   DrugBank; DB02096; FR221647.
DR   DrugBank; DB03572; FR230513.
DR   DrugBank; DB03220; FR233623.
DR   DrugBank; DB02830; FR236913.
DR   DrugBank; DB03370; FR239087.
DR   DrugBank; DB01280; Nelarabine.
DR   DrugBank; DB00552; Pentostatin.
DR   DrugBank; DB04440; Purine Riboside.
DR   DrugBank; DB00277; Theophylline.
DR   DrugBank; DB00194; Vidarabine.
DR   GuidetoPHARMACOLOGY; 1230; -.
DR   iPTMnet; P00813; -.
DR   PhosphoSitePlus; P00813; -.
DR   SwissPalm; P00813; -.
DR   BioMuta; ADA; -.
DR   DMDM; 113339; -.
DR   EPD; P00813; -.
DR   MaxQB; P00813; -.
DR   PaxDb; P00813; -.
DR   PeptideAtlas; P00813; -.
DR   PRIDE; P00813; -.
DR   TopDownProteomics; P00813; -.
DR   DNASU; 100; -.
DR   Ensembl; ENST00000372874; ENSP00000361965; ENSG00000196839.
DR   GeneID; 100; -.
DR   KEGG; hsa:100; -.
DR   UCSC; uc002xmj.4; human.
DR   CTD; 100; -.
DR   DisGeNET; 100; -.
DR   GeneCards; ADA; -.
DR   GeneReviews; ADA; -.
DR   HGNC; HGNC:186; ADA.
DR   HPA; CAB004307; -.
DR   HPA; HPA001399; -.
DR   HPA; HPA023884; -.
DR   MalaCards; ADA; -.
DR   MIM; 102700; phenotype.
DR   MIM; 608958; gene.
DR   neXtProt; NX_P00813; -.
DR   OpenTargets; ENSG00000196839; -.
DR   Orphanet; 39041; Omenn syndrome.
DR   Orphanet; 277; Severe combined immunodeficiency due to adenosine deaminase deficiency.
DR   PharmGKB; PA24503; -.
DR   eggNOG; KOG1097; Eukaryota.
DR   eggNOG; COG1816; LUCA.
DR   GeneTree; ENSGT00730000111151; -.
DR   HOGENOM; HOG000218816; -.
DR   HOVERGEN; HBG001718; -.
DR   InParanoid; P00813; -.
DR   KO; K01488; -.
DR   OMA; MPAIAGC; -.
DR   OrthoDB; EOG091G0NL8; -.
DR   PhylomeDB; P00813; -.
DR   TreeFam; TF314270; -.
DR   BioCyc; MetaCyc:HS02191-MONOMER; -.
DR   BRENDA; 3.5.4.4; 2681.
DR   Reactome; R-HSA-74217; Purine salvage.
DR   SABIO-RK; P00813; -.
DR   SignaLink; P00813; -.
DR   ChiTaRS; ADA; human.
DR   EvolutionaryTrace; P00813; -.
DR   GeneWiki; Adenosine_deaminase; -.
DR   GenomeRNAi; 100; -.
DR   PRO; PR:P00813; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000196839; -.
DR   CleanEx; HS_ADA; -.
DR   ExpressionAtlas; P00813; baseline and differential.
DR   Genevisible; P00813; HS.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-SubCell.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0060205; C:cytoplasmic vesicle lumen; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0032839; C:dendrite cytoplasm; IEA:Ensembl.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IEA:Ensembl.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0004000; F:adenosine deaminase activity; IDA:UniProtKB.
DR   GO; GO:0001883; F:purine nucleoside binding; IEA:Ensembl.
DR   GO; GO:0008270; F:zinc ion binding; IMP:UniProtKB.
DR   GO; GO:0006154; P:adenosine catabolic process; IDA:UniProtKB.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0046061; P:dATP catabolic process; IEA:Ensembl.
DR   GO; GO:0006157; P:deoxyadenosine catabolic process; IEA:Ensembl.
DR   GO; GO:0048566; P:embryonic digestive tract development; IEA:Ensembl.
DR   GO; GO:0002314; P:germinal center B cell differentiation; IEA:Ensembl.
DR   GO; GO:0001821; P:histamine secretion; IEA:Ensembl.
DR   GO; GO:0046101; P:hypoxanthine biosynthetic process; IEA:Ensembl.
DR   GO; GO:0046103; P:inosine biosynthetic process; IDA:MGI.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0048286; P:lung alveolus development; IEA:Ensembl.
DR   GO; GO:0060169; P:negative regulation of adenosine receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0042323; P:negative regulation of circadian sleep/wake cycle, non-REM sleep; IEA:Ensembl.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0002686; P:negative regulation of leukocyte migration; IEA:Ensembl.
DR   GO; GO:0002906; P:negative regulation of mature B cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0070256; P:negative regulation of mucus secretion; IEA:Ensembl.
DR   GO; GO:0060407; P:negative regulation of penile erection; IEA:Ensembl.
DR   GO; GO:0070244; P:negative regulation of thymocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0048541; P:Peyer's patch development; IEA:Ensembl.
DR   GO; GO:0001890; P:placenta development; IEA:Ensembl.
DR   GO; GO:0046638; P:positive regulation of alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IEA:Ensembl.
DR   GO; GO:0050850; P:positive regulation of calcium-mediated signaling; IEA:Ensembl.
DR   GO; GO:0002636; P:positive regulation of germinal center formation; IEA:Ensembl.
DR   GO; GO:0010460; P:positive regulation of heart rate; IEA:Ensembl.
DR   GO; GO:0045987; P:positive regulation of smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0033089; P:positive regulation of T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0050862; P:positive regulation of T cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0032261; P:purine nucleotide salvage; IMP:UniProtKB.
DR   GO; GO:0009168; P:purine ribonucleoside monophosphate biosynthetic process; IEA:InterPro.
DR   GO; GO:0043101; P:purine-containing compound salvage; TAS:Reactome.
DR   GO; GO:0033632; P:regulation of cell-cell adhesion mediated by integrin; IDA:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0042542; P:response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IDA:UniProtKB.
DR   GO; GO:0043278; P:response to morphine; IEA:Ensembl.
DR   GO; GO:0033197; P:response to vitamin E; IEA:Ensembl.
DR   GO; GO:0042110; P:T cell activation; IDA:UniProtKB.
DR   GO; GO:0001829; P:trophectodermal cell differentiation; IEA:Ensembl.
DR   GO; GO:0046111; P:xanthine biosynthetic process; IEA:Ensembl.
DR   CDD; cd01320; ADA; 1.
DR   HAMAP; MF_00540; A_deaminase; 1.
DR   InterPro; IPR006650; A/AMP_deam_AS.
DR   InterPro; IPR001365; A/AMP_deaminase_dom.
DR   InterPro; IPR028893; A_deaminase.
DR   InterPro; IPR006330; Ado/ade_deaminase.
DR   InterPro; IPR032466; Metal_Hydrolase.
DR   Pfam; PF00962; A_deaminase; 1.
DR   SUPFAM; SSF51556; SSF51556; 1.
DR   TIGRFAMs; TIGR01430; aden_deam; 1.
DR   PROSITE; PS00485; A_DEAMINASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell adhesion; Cell junction;
KW   Cell membrane; Complete proteome; Cytoplasm; Cytoplasmic vesicle;
KW   Direct protein sequencing; Disease mutation;
KW   Hereditary hemolytic anemia; Hydrolase; Lysosome; Membrane;
KW   Metal-binding; Nucleotide metabolism; Polymorphism;
KW   Reference proteome; SCID; Zinc.
FT   INIT_MET      1      1       Removed. {ECO:0000269|Ref.8}.
FT   CHAIN         2    363       Adenosine deaminase.
FT                                /FTId=PRO_0000194352.
FT   REGION      126    143       Required for binding to DDP4.
FT                                {ECO:0000269|PubMed:15016824}.
FT   ACT_SITE    217    217       Proton donor.
FT                                {ECO:0000250|UniProtKB:P03958}.
FT   METAL        15     15       Zinc; catalytic. {ECO:0000305|Ref.24}.
FT   METAL        17     17       Zinc; catalytic. {ECO:0000305|Ref.24}.
FT   METAL       214    214       Zinc; catalytic. {ECO:0000305|Ref.24}.
FT   METAL       295    295       Zinc; catalytic. {ECO:0000305|Ref.24}.
FT   BINDING      17     17       Substrate. {ECO:0000244|PDB:3IAR,
FT                                ECO:0000269|Ref.24}.
FT   BINDING      19     19       Substrate. {ECO:0000244|PDB:3IAR,
FT                                ECO:0000269|Ref.24}.
FT   BINDING     184    184       Substrate; via amide nitrogen.
FT                                {ECO:0000244|PDB:3IAR,
FT                                ECO:0000269|Ref.24}.
FT   BINDING     296    296       Substrate. {ECO:0000244|PDB:3IAR,
FT                                ECO:0000269|Ref.24}.
FT   SITE         58     58       Important for interaction with adenosine
FT                                receptors and increasing their affinity
FT                                for agonists.
FT                                {ECO:0000269|PubMed:23193172}.
FT   SITE         62     62       Important for interaction with adenosine
FT                                receptors and increasing their affinity
FT                                for agonists.
FT                                {ECO:0000269|PubMed:23193172}.
FT   SITE        238    238       Important for catalytic activity.
FT                                {ECO:0000250|UniProtKB:P03958}.
FT   MOD_RES       2      2       N-acetylalanine. {ECO:0000269|Ref.8}.
FT   MOD_RES      54     54       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     232    232       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   VARIANT       8      8       D -> N (polymorphism; allele ADA*2; found
FT                                in about 10% of the population; affects
FT                                duration and intensity of deep sleep;
FT                                enhances negative effects of sleep loss
FT                                during sleep deprivation; may have a
FT                                protective role against male infertility;
FT                                20% to 30% decrease in activity;
FT                                dbSNP:rs73598374).
FT                                {ECO:0000269|PubMed:16221767,
FT                                ECO:0000269|PubMed:21734253,
FT                                ECO:0000269|PubMed:26166670,
FT                                ECO:0000269|PubMed:8031011}.
FT                                /FTId=VAR_002209.
FT   VARIANT      15     15       H -> D (in ADASCID; loss of activity;
FT                                dbSNP:rs121908725).
FT                                {ECO:0000269|PubMed:7599635}.
FT                                /FTId=VAR_002210.
FT   VARIANT      20     20       G -> R (in ADASCID; loss of activity;
FT                                dbSNP:rs121908724).
FT                                {ECO:0000269|PubMed:8299233}.
FT                                /FTId=VAR_002211.
FT   VARIANT      74     74       G -> C (in ADASCID; delayed-onset;
FT                                dbSNP:rs121908730).
FT                                {ECO:0000269|PubMed:10200056}.
FT                                /FTId=VAR_002212.
FT   VARIANT      76     76       R -> W (in ADASCID; dbSNP:rs121908736).
FT                                {ECO:0000269|PubMed:2166947}.
FT                                /FTId=VAR_002213.
FT   VARIANT      80     80       K -> R (in dbSNP:rs11555566).
FT                                {ECO:0000269|PubMed:8589684}.
FT                                /FTId=VAR_002214.
FT   VARIANT      83     83       A -> D (in ADASCID; loss of activity;
FT                                dbSNP:rs121908726).
FT                                {ECO:0000269|PubMed:7599635}.
FT                                /FTId=VAR_002215.
FT   VARIANT      97     97       Y -> C (in ADASCID; unknown pathological
FT                                significance; loss of activity on its
FT                                own; total loss of activity; when
FT                                associated with V-106;
FT                                dbSNP:rs267606634).
FT                                {ECO:0000269|PubMed:9361033}.
FT                                /FTId=VAR_076954.
FT   VARIANT     101    101       R -> L (in ADASCID; dbSNP:rs121908720).
FT                                {ECO:0000269|PubMed:8227344}.
FT                                /FTId=VAR_002216.
FT   VARIANT     101    101       R -> Q (in ADASCID; loss of activity;
FT                                dbSNP:rs28930970).
FT                                {ECO:0000269|PubMed:3839802}.
FT                                /FTId=VAR_002218.
FT   VARIANT     101    101       R -> W (in ADASCID; dbSNP:rs28930969).
FT                                {ECO:0000269|PubMed:3182793}.
FT                                /FTId=VAR_002217.
FT   VARIANT     106    106       L -> V (in ADASCID; unknown pathological
FT                                significance; 30% of activity; total loss
FT                                of activity; when associated with C-97;
FT                                dbSNP:rs267606635).
FT                                {ECO:0000269|PubMed:9361033}.
FT                                /FTId=VAR_076955.
FT   VARIANT     107    107       L -> P (in ADASCID; dbSNP:rs121908739).
FT                                {ECO:0000269|PubMed:2166947}.
FT                                /FTId=VAR_002219.
FT   VARIANT     129    129       V -> M (in ADASCID; delayed-onset;
FT                                dbSNP:rs121908731).
FT                                {ECO:0000269|PubMed:10200056}.
FT                                /FTId=VAR_002220.
FT   VARIANT     140    140       G -> E (in ADASCID; dbSNP:rs121908732).
FT                                {ECO:0000269|PubMed:10200056}.
FT                                /FTId=VAR_002221.
FT   VARIANT     142    142       R -> Q (in a pancreatic ductal
FT                                adenocarcinoma sample; somatic mutation;
FT                                dbSNP:rs61732239).
FT                                {ECO:0000269|PubMed:18772397,
FT                                ECO:0000269|PubMed:8589684}.
FT                                /FTId=VAR_002222.
FT   VARIANT     149    149       R -> Q (in ADASCID; dbSNP:rs121908737).
FT                                {ECO:0000269|PubMed:2166947}.
FT                                /FTId=VAR_002223.
FT   VARIANT     149    149       R -> W (in ADASCID; dbSNP:rs121908733).
FT                                {ECO:0000269|PubMed:10200056}.
FT                                /FTId=VAR_002224.
FT   VARIANT     152    152       L -> M (in an individual with partial ADA
FT                                deficiency but no immunodeficiency; 1,5%
FT                                of activity; dbSNP:rs121908728).
FT                                {ECO:0000269|PubMed:9225964}.
FT                                /FTId=VAR_002225.
FT   VARIANT     156    156       R -> C (in ADASCID; dbSNP:rs121908735).
FT                                {ECO:0000269|PubMed:1284479}.
FT                                /FTId=VAR_002226.
FT   VARIANT     156    156       R -> H (in ADASCID; loss of activity;
FT                                dbSNP:rs121908722).
FT                                {ECO:0000269|PubMed:8227344}.
FT                                /FTId=VAR_002227.
FT   VARIANT     177    177       V -> M (in ADASCID; loss of activity;
FT                                dbSNP:rs121908719).
FT                                {ECO:0000269|PubMed:8227344}.
FT                                /FTId=VAR_002228.
FT   VARIANT     179    179       A -> D (in ADASCID; loss of activity;
FT                                dbSNP:rs121908727).
FT                                {ECO:0000269|PubMed:7599635}.
FT                                /FTId=VAR_002229.
FT   VARIANT     199    199       Q -> P (in ADASCID; delayed-onset;
FT                                dbSNP:rs121908734).
FT                                {ECO:0000269|PubMed:10200056}.
FT                                /FTId=VAR_002230.
FT   VARIANT     211    211       R -> C (in ADASCID; late onset; 4% of
FT                                activity; dbSNP:rs121908740).
FT                                {ECO:0000269|PubMed:2166947,
FT                                ECO:0000269|PubMed:9361033}.
FT                                /FTId=VAR_002231.
FT   VARIANT     211    211       R -> H (in ADASCID; dbSNP:rs121908716).
FT                                {ECO:0000269|PubMed:3182793}.
FT                                /FTId=VAR_002232.
FT   VARIANT     215    215       A -> T (in ADASCID; 8% of activity;
FT                                dbSNP:rs114025668).
FT                                {ECO:0000269|PubMed:2166947,
FT                                ECO:0000269|PubMed:9361033}.
FT                                /FTId=VAR_002233.
FT   VARIANT     216    216       G -> R (in ADASCID; severe;
FT                                dbSNP:rs121908723).
FT                                {ECO:0000269|PubMed:8227344}.
FT                                /FTId=VAR_002234.
FT   VARIANT     233    233       T -> I (in an individual with partial ADA
FT                                deficiency but no immunodeficiency; 20%
FT                                of activity; dbSNP:rs121908729).
FT                                {ECO:0000269|PubMed:9225964,
FT                                ECO:0000269|PubMed:9361033}.
FT                                /FTId=VAR_002235.
FT   VARIANT     274    274       P -> L (in ADASCID; dbSNP:rs121908738).
FT                                {ECO:0000269|PubMed:2166947}.
FT                                /FTId=VAR_002236.
FT   VARIANT     291    291       S -> L (in ADASCID; dbSNP:rs121908721).
FT                                {ECO:0000269|PubMed:1284479,
FT                                ECO:0000269|PubMed:8227344}.
FT                                /FTId=VAR_002237.
FT   VARIANT     297    297       P -> Q (in ADASCID; dbSNP:rs121908718).
FT                                {ECO:0000269|PubMed:2783588}.
FT                                /FTId=VAR_002238.
FT   VARIANT     304    304       L -> R (in ADASCID; loss of activity;
FT                                dbSNP:rs199422327).
FT                                /FTId=VAR_002239.
FT   VARIANT     329    329       A -> V (in ADASCID; dbSNP:rs121908715).
FT                                {ECO:0000269|PubMed:3182793}.
FT                                /FTId=VAR_002240.
FT   VARIANT     337    337       Missing (in ADASCID).
FT                                /FTId=VAR_002241.
FT   MUTAGEN      58     58       L->A: Decreases enzyme activity by
FT                                reducing substrate affinity and maximum
FT                                velocity; abolishes ADORA1 and ADORA2A
FT                                modulator function.
FT                                {ECO:0000269|PubMed:23193172}.
FT   MUTAGEN      60     60       D->A: Moderately reduces enzyme activity;
FT                                reduces ADORA1 and ADORA2A modulation.
FT                                {ECO:0000269|PubMed:23193172}.
FT   MUTAGEN      61     61       F->A: Decreases enzyme activity by
FT                                reducing maximum velocity; reduces ADORA1
FT                                modulation.
FT                                {ECO:0000269|PubMed:23193172}.
FT   MUTAGEN      62     62       L->A: Decreases enzyme activity by
FT                                reducing substrate affinity and maximum
FT                                velocity; abolishes ADORA1 and ADORA2A
FT                                modulator function.
FT                                {ECO:0000269|PubMed:23193172}.
FT   MUTAGEN      64     64       K->A: Moderately reduces enzyme activity;
FT                                no change in ADORA1 and ADORA2A
FT                                modulation.
FT                                {ECO:0000269|PubMed:23193172}.
FT   MUTAGEN      65     65       F->A: Decreases enzyme activity by
FT                                reducing substrate affinity and maximum
FT                                velocity; reduces ADORA1 and ADORA2A
FT                                modulation.
FT                                {ECO:0000269|PubMed:23193172}.
FT   MUTAGEN      66     66       D->A: No change in enzyme activity; no
FT                                change in ADORA1 and ADORA2A modulation.
FT                                {ECO:0000269|PubMed:23193172}.
FT   MUTAGEN      69     69       M->A: Decreases enzyme activity by
FT                                reducing maximum velocity; reduces
FT                                ADORA2A modulation.
FT                                {ECO:0000269|PubMed:23193172}.
FT   MUTAGEN     115    115       I->A: No change in enzyme activity; no
FT                                change in ADORA1 and ADORA2A modulation.
FT                                {ECO:0000269|PubMed:23193172}.
FT   MUTAGEN     118    118       N->A: Moderately reduces enzyme activity;
FT                                no change in ADORA1 and ADORA2A
FT                                modulation.
FT                                {ECO:0000269|PubMed:23193172}.
FT   MUTAGEN     155    155       M->A: Decreases enzyme activity by
FT                                reducing substrate affinity and maximum
FT                                velocity. {ECO:0000269|PubMed:23193172}.
FT   MUTAGEN     157    157       H->A: Moderately reduces enzyme activity;
FT                                no change in ADORA1 and ADORA2A
FT                                modulation.
FT                                {ECO:0000269|PubMed:23193172}.
FT   MUTAGEN     184    184       G->Q: Moderately reduces enzyme activity.
FT                                {ECO:0000269|PubMed:23193172}.
FT   MUTAGEN     185    185       D->A: Moderately reduces enzyme activity.
FT                                {ECO:0000269|PubMed:23193172}.
FT   MUTAGEN     194    194       L->A: No change in enzyme activity.
FT                                {ECO:0000269|PubMed:23193172}.
FT   CONFLICT    340    340       K -> R (in Ref. 5; BAD97117).
FT                                {ECO:0000305}.
FT   STRAND       11     13       {ECO:0000244|PDB:3IAR}.
FT   HELIX        18     20       {ECO:0000244|PDB:3IAR}.
FT   HELIX        24     34       {ECO:0000244|PDB:3IAR}.
FT   HELIX        43     50       {ECO:0000244|PDB:3IAR}.
FT   HELIX        58     62       {ECO:0000244|PDB:3IAR}.
FT   HELIX        63     67       {ECO:0000244|PDB:3IAR}.
FT   HELIX        69     72       {ECO:0000244|PDB:3IAR}.
FT   HELIX        76     91       {ECO:0000244|PDB:3IAR}.
FT   TURN         92     94       {ECO:0000244|PDB:3IAR}.
FT   STRAND       95    102       {ECO:0000244|PDB:3IAR}.
FT   HELIX       104    107       {ECO:0000244|PDB:3IAR}.
FT   STRAND      109    111       {ECO:0000244|PDB:3IAR}.
FT   HELIX       116    118       {ECO:0000244|PDB:3IAR}.
FT   HELIX       126    144       {ECO:0000244|PDB:3IAR}.
FT   STRAND      147    155       {ECO:0000244|PDB:3IAR}.
FT   HELIX       159    161       {ECO:0000244|PDB:3IAR}.
FT   HELIX       162    171       {ECO:0000244|PDB:3IAR}.
FT   TURN        172    176       {ECO:0000244|PDB:3IAR}.
FT   STRAND      177    184       {ECO:0000244|PDB:3IAR}.
FT   HELIX       191    193       {ECO:0000244|PDB:3IAR}.
FT   HELIX       195    207       {ECO:0000244|PDB:3IAR}.
FT   STRAND      210    219       {ECO:0000244|PDB:3IAR}.
FT   HELIX       221    229       {ECO:0000244|PDB:3IAR}.
FT   STRAND      234    238       {ECO:0000244|PDB:3IAR}.
FT   HELIX       240    244       {ECO:0000244|PDB:3IAR}.
FT   HELIX       246    254       {ECO:0000244|PDB:3IAR}.
FT   STRAND      258    261       {ECO:0000244|PDB:3IAR}.
FT   HELIX       263    268       {ECO:0000244|PDB:3IAR}.
FT   STRAND      270    272       {ECO:0000244|PDB:3IAR}.
FT   HELIX       279    285       {ECO:0000244|PDB:3IAR}.
FT   STRAND      290    292       {ECO:0000244|PDB:3IAR}.
FT   HELIX       297    300       {ECO:0000244|PDB:3IAR}.
FT   HELIX       304    315       {ECO:0000244|PDB:3IAR}.
FT   HELIX       319    331       {ECO:0000244|PDB:3IAR}.
FT   STRAND      333    335       {ECO:0000244|PDB:3IAR}.
FT   HELIX       337    351       {ECO:0000244|PDB:3IAR}.
FT   HELIX       355    362       {ECO:0000244|PDB:3IAR}.
SQ   SEQUENCE   363 AA;  40764 MW;  786BC5085CA9AFCB CRC64;
     MAQTPAFDKP KVELHVHLDG SIKPETILYY GRRRGIALPA NTAEGLLNVI GMDKPLTLPD
     FLAKFDYYMP AIAGCREAIK RIAYEFVEMK AKEGVVYVEV RYSPHLLANS KVEPIPWNQA
     EGDLTPDEVV ALVGQGLQEG ERDFGVKARS ILCCMRHQPN WSPKVVELCK KYQQQTVVAI
     DLAGDETIPG SSLLPGHVQA YQEAVKSGIH RTVHAGEVGS AEVVKEAVDI LKTERLGHGY
     HTLEDQALYN RLRQENMHFE ICPWSSYLTG AWKPDTEHAV IRLKNDQANY SLNTDDPLIF
     KSTLDTDYQM TKRDMGFTEE EFKRLNINAA KSSFLPEDEK RELLDLLYKA YGMPPSASAG
     QNL
//
